Will Crowdfunding Fuel a Boom or Bubble for High-Tech Executive Hiring?
Now that the Jumpstart Our Business Startups (JOBS) Act has been signed into law, the hope is that regulatory restrictions to fund startups and small businesses through the Crowdfunding will open up new avenues for raising funds that were otherwise restricted.
In a recent interview done by Rafe Needleman on CNET (see video), the pros and cons of the Crowdfunding provision in the JOBS act were discussed with guests George Zachary, Chance Barnett, and Tim Rowe. On balance the consensus of this panel would indicate that the law will be a catalyst for growth for startups and in particular for high-tech firms looking to jumpstart development by raising early rounds.
What is still an unknown is whether certain sectors like medical devices, biotechnology, nanotechnology and others that require a longer runway to commercial success, will benefit. Many post meltdown investors do not have the patience or stomach to endure a protracted product development cycle that some of these areas require.
Even though the JOBS Act does not directly impact jobs as such, the collateral effect over the longer term will be that more jobs will result from the additional capital to permit the formation, continuation and stability of startups. Firms that have established some level of success after initial funding, could go public via an I.P.O., sooner and with less restriction thus benefiting the initial investors and expanding further the viability of the jobs created.
As statistics show conclusively, the engine of new job creation is powered by newly formed companies. So it would follow that jobs at all organizational levels from the executive ranks to non-management will increase as money fuels new startups.
As forward looking executives and leaders in sci-tech based organizations, assess the new and novel technologies, biomimicry is one area that is being looked at as a source of next-generation products.
With medical device makers looking for next-gen products that can deliver greater efficacy and still be cost competitive, flexible organic transistors may play an important role.
The Senate has just approved the Jump-Start Our Business Startups (or JOBS) Act and is on track to go back to the House for full approval within days.
In a show of good will, several Life Science Giants have chipped in to bolster the relief efforts in Japan. As reported by MassDevice, Abbott Laboratories and Amgen kick in a combined $4 million toward relief efforts in Japan after a large earthquake and tsunami devastated the country March 11. 
Recession, depression, meltdown. You seen and heard it all in the news. These events have kept unemployment high and caused much disruption in the conduct of commerce.
Though 
In an after-hours scene, an employee logs in to his company account, inserts his jump drive, and downloads thousands of records. The final destination of these records is anyone’s guess.
Reinventing the Medical Device Company
For the overall US economy to continue improving, sustained economic prosperity depends in no small measure on continual innovation. However, with burdens placed on device companies in the form of new taxation, Continue reading →